These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 4982681

  • 1. Ocular complications of chlorpromazine therapy.
    Petrohelos MA, Tricoulis D.
    Ophthalmologica; 1969; 158 Suppl():469-76. PubMed ID: 4982681
    [No Abstract] [Full Text] [Related]

  • 2. Ocular complications of phenothiazines.
    Mathalone MB.
    Trans Ophthalmol Soc U K (1962); 1966; 86():77-88. PubMed ID: 5226613
    [No Abstract] [Full Text] [Related]

  • 3. [Ophthalmologic study of patients receiving psychotropic drugs].
    Gol'dovskaia IL.
    Zh Nevropatol Psikhiatr Im S S Korsakova; 1970 May; 70(5):759-62. PubMed ID: 5311196
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Ocular complications related to phenothiazines.
    Siddall JR.
    Dis Nerv Syst; 1968 Mar; 29(3):Suppl:10-3. PubMed ID: 4876740
    [No Abstract] [Full Text] [Related]

  • 7. Ocular complications of chlorpromazine therapy.
    Petrohelos MA, Tricoulis D.
    Ophthalmologica; 1969 Mar; 159(1):31-8. PubMed ID: 4984273
    [No Abstract] [Full Text] [Related]

  • 8. [Damage to eyes through conservative therapy].
    Kleberger E.
    Klin Monbl Augenheilkd; 1967 Mar; 151(6):777-801. PubMed ID: 4874408
    [No Abstract] [Full Text] [Related]

  • 9. Toxic effects of phenothiazines on the eye.
    Boet DJ.
    Doc Ophthalmol; 1970 Jul 24; 28(1):1-69. PubMed ID: 5312274
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. [Ultrastructural study of ocular pigmentation due to phenothiazines].
    Sizaret P, Rossazza C, Brassart B.
    Rev Otoneuroophtalmol; 1975 Jul 24; 47(4):247-51. PubMed ID: 1215727
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Prolonged treatment of psychotic states. (Over 1600 patients treated continuously 3 to 7 years).
    Goldman D.
    Dis Nerv Syst; 1968 Mar 24; 29(3):Suppl:51-7. PubMed ID: 4970486
    [No Abstract] [Full Text] [Related]

  • 17. Cutaneous and ocular changes associated with the use of chlorpromazine.
    Wolf ME, Richer S, Berk MA, Mosnaim AD.
    Int J Clin Pharmacol Ther Toxicol; 1993 Aug 24; 31(8):365-7. PubMed ID: 8225679
    [Abstract] [Full Text] [Related]

  • 18. Long term evolution of the side-effect lens opacities induced by chlorpromazine prolonged therapy.
    Baron JB, Rivoalan Y, Morel P.
    Agressologie; 1971 Aug 24; 12(1):57-60. PubMed ID: 5088348
    [No Abstract] [Full Text] [Related]

  • 19. Ocular changes occurring with prolonged high dose chlorpromazine therapy. Results from a collaborative study.
    Prien RF, DeLong SL, Cole JO, Levine J.
    Arch Gen Psychiatry; 1970 Nov 24; 23(5):464-8. PubMed ID: 5478574
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.